Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 5/20 | 0.36 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571515 | 0.83 | JAK3 (0.39) | CYP2C19POLBALDH1A1CA1CA2 | |
| SCHEMBL10267180 | 0.78 | CYP2C9 (0.52) | CYP2C19POLBALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL10266797 | 0.77 | HDAC1 (0.38) | CYP2C19POLBALDH1A1CA1CA2 | |
| SCHEMBL12513768 | 0.76 | TNF (0.35) | HSD17B10TNF | |
| SCHEMBL12215154 | 0.76 | TNF (0.35) | HSD17B10RAB9ATNF | |
| SCHEMBL12513704 | 0.75 | TNF (0.33) | TNF | |
| SCHEMBL11963570 | 0.73 | CYP2C9 (0.38) | CYP2C19POLBALDH1A1KDM4ELMNA | |
| SCHEMBL13325347 | 0.73 | ERN1 (0.37) | TNF | |
| SCHEMBL13325432 | 0.71 | ADRA2A (0.44) | ALDH1A1KDM4EHSD17B10SMN1; SMN2TNF | |
| SCHEMBL26844421 | 0.69 | ALDH1A1 (0.44) | POLBALDH1A1KDM4EHSD17B10NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601174-B1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2014-11-26 | — | — | EP | disclosed |
| US-8450361-B2 | Substituted indole and azaindole oxoacetyl piperazinamide derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450361-B2 | Substituted indole and azaindole oxoacetyl piperazinamide derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120202775-A1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| US-20120202775-A1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2012-08-09 | — | — | US | disclosed |
| WO-2012019003-A1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202775-A1 | SUBSTITUTED INDOLE AND AZAINDOLE OXOACETYL PIPERAZINAMIDE DERIVATIVES | IDO1, IDO2, INMT | CYP2C19 171/4885POLB 1047/4885ALDH1A1 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.